Gilead Sciences (GILD) shares oversold argues BofA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BofA Securities Upgrades Gilead Sciences (GILD) to Buy on HIV drug upside
September 8, 2023 6:05 AM EDT(Updated - September 8, 2023 6:40 AM EDT)
BofA Securities analyst Geoff Meacham upgraded Gilead Sciences (NASDAQ: GILD) from Neutral to Buy with a price target of $95.00 (from $88.00).
The analyst commented "We are upgrading GILD shares to Buy (from Neutral) and raising our PO to... More
Gilead Sciences (GILD) Prices $2B Notes Offering
September 8, 2023 5:46 AM EDTGilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1... More
Amgen and Biogen 'look attractive' - HSBC
September 6, 2023 11:39 AM EDTHSBC initiated coverage of 11 US biopharmaceutical and healthcare stocks in a note to clients on Wednesday.
Analyst Morten Herholdt assigned Actinium Pharma (NYSE: ATNM), Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), Bluebird... More
HSBC Starts Gilead Sciences (GILD) at Reduce
September 6, 2023 3:14 AM EDTHSBC analyst Morten Herholdt initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Reduce rating and a price target of $71.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $75.16 yesterday.
... More